JP2004501962A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501962A5
JP2004501962A5 JP2002506712A JP2002506712A JP2004501962A5 JP 2004501962 A5 JP2004501962 A5 JP 2004501962A5 JP 2002506712 A JP2002506712 A JP 2002506712A JP 2002506712 A JP2002506712 A JP 2002506712A JP 2004501962 A5 JP2004501962 A5 JP 2004501962A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
symptom
inflammatory disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002506712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FI2001/000638 external-priority patent/WO2002002090A2/en
Publication of JP2004501962A publication Critical patent/JP2004501962A/ja
Publication of JP2004501962A5 publication Critical patent/JP2004501962A5/ja
Withdrawn legal-status Critical Current

Links

JP2002506712A 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤 Withdrawn JP2004501962A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21634100P 2000-07-05 2000-07-05
PCT/FI2001/000638 WO2002002090A2 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases

Publications (2)

Publication Number Publication Date
JP2004501962A JP2004501962A (ja) 2004-01-22
JP2004501962A5 true JP2004501962A5 (enExample) 2005-03-03

Family

ID=22806663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002507795A Withdrawn JP2004502682A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤
JP2002506712A Withdrawn JP2004501962A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002507795A Withdrawn JP2004502682A (ja) 2000-07-05 2001-07-04 銅含有アミン・オキシダーゼの阻害剤

Country Status (14)

Country Link
US (2) US6624202B2 (enExample)
EP (2) EP1301495A2 (enExample)
JP (2) JP2004502682A (enExample)
CN (2) CN1450997A (enExample)
AU (3) AU2001282163B2 (enExample)
CA (2) CA2414799A1 (enExample)
HU (2) HUP0301625A3 (enExample)
IL (2) IL153767A0 (enExample)
NO (2) NO20026283L (enExample)
NZ (2) NZ523464A (enExample)
PL (2) PL360353A1 (enExample)
RU (2) RU2003103291A (enExample)
WO (2) WO2002002541A2 (enExample)
ZA (2) ZA200300063B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
TWI336696B (en) 2003-01-27 2011-02-01 Astellas Pharma Inc Thiazole derivatives
KR20120045062A (ko) * 2003-03-31 2012-05-08 가부시키가이샤 아루떼꾸 우에노 혈관 과투과 질환의 치료방법
US7499847B2 (en) 2003-05-26 2009-03-03 Biotie Therapies Corporation Crystalline VAP-1 and uses thereof
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
CA2549029A1 (en) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
EP1791835A2 (en) * 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Tdk株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8426587B2 (en) * 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為vap-1抑制劑之用途
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
EP2357252A4 (en) 2008-09-03 2012-05-16 Univ Barcelona Autonoma METHOD AND COMPOSITIONS FOR TREATING AND DIAGNOSIS OF A HEMORRHAGIC CONVERSION
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
RU2010145439A (ru) 2010-11-08 2012-05-20 Виктор Вениаминович Тец (RU) Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
KR101879011B1 (ko) * 2011-03-15 2018-07-16 아스테라스 세이야쿠 가부시키가이샤 구아니딘 화합물
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
RU2595868C1 (ru) 2015-03-27 2016-08-27 Виктор Вениаминович Тец Лекарственное средство с гепатопротекторной активностью
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
US20180360808A1 (en) 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377345A (en) * 1966-09-23 1968-04-09 Dow Chemical Co Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof
US3486916A (en) 1966-12-22 1969-12-30 William A Cordon Cement mixes and the production of articles therefrom
SE320311B (enExample) 1968-07-15 1970-02-02 Mo Och Domsjoe Ab
WO1993023023A1 (en) * 1992-05-15 1993-11-25 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US5413634A (en) 1993-08-06 1995-05-09 Arco Chemical Technology, L.P. Cement composition
CA2117585C (en) 1993-09-14 2001-06-05 Edward T. Shawl Cement composition
WO1996006058A1 (en) 1994-08-25 1996-02-29 W.R. Grace & Co.-Conn. Shrinkage reduction cement composition
US5618344A (en) 1995-03-06 1997-04-08 W. R. Grace & Co.-Conn. Cement composition
US5556460A (en) 1995-09-18 1996-09-17 W.R. Grace & Co.-Conn. Drying shrinkage cement admixture
US5603760A (en) 1995-09-18 1997-02-18 W. R. Grace & Co.-Conn. Cement admixture capable of inhibiting drying shrinkage and method of using same
CN1450997A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂

Similar Documents

Publication Publication Date Title
RU2003103286A (ru) Ингибиторы медьсодержащих аминооксидаз
JP2005501035A5 (enExample)
JP2004502682A5 (enExample)
CN100477992C (zh) 取代的哌嗪和哌啶钙通道封闭剂
US20240050401A1 (en) Methods of treating social function disorders
JP2019059760A5 (enExample)
JPS584752A (ja) カルボキシアミド誘導体及びその製造法
JP2009542595A5 (enExample)
RU2004103869A (ru) Карбоциклические гидразины в качестве ингибиторов медьсодержащх аминоксидаз
TW200817340A (en) Compounds with combined SERT, 5-HT3 and 5-HT1A activity
JP2007508360A5 (enExample)
TNSN04136A1 (en) Aza-arylpiperazines
EA016687B8 (ru) Производные циклопропиламида
JP2010523623A (ja) P2x7調節因子としてのピラゾール誘導体
JP2010511631A5 (enExample)
JP2005508872A5 (enExample)
JP2007522135A5 (enExample)
AU2003237724A1 (en) Tolterodine salts
JP2023531869A5 (enExample)
TW201110962A (en) Carbocyclic GlyT1 receptor antagonists
CN103228618A (zh) 新化合物及其医药用途
CN1278728A (zh) 治疗呼吸系统疾病的组合物和方法
ATE475640T1 (de) Antagonisten des opioidrezeptors
JP2006503816A5 (enExample)
JP2006124380A (ja) 医薬組成物